Caixa leads €2.2m series-B for Inbiomotion

The Caixa Innvierte BioMed II fund led the round alongside existing investor Ysios Capital and Fundación Vila Casas. The vehicle is managed by Caixa Capital Risc, the venture capital arm of La Caixa.

The fresh capital will allow the company to boost its product development, completing its clinical validation in the next two years, and to expand the business in the breast and prostate cancer markets.

Previous investment
In July 2012, Spanish life sciences venture capital firm Ysios led a €2m series-A round for Inbiomotion, through its Ysios BioFund I fund. Additional investors Fundació Vila Casas and JVRisk Technologies participated in the round.

Company
Founded in 2012 and based in Barcelona, Inbiomotion develops diagnostic tests to predict bone metastasis for cancer patients.

The company is a spinout from Growth Control and Cancer Metastasis group at the Institute for Biomedical Research of Barcelona, associated with the University of Barcelona.

People
Caixa Capital Risc – Jose Antonio Mesa (director of investments).
Inbiomotion – Roger Gomis (founder).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Healthcare
• Southern Europe
• Early-stage
• Spain
• La Caixa
• Caixa Capital Risc
• Ysios Capital